BPGAM
SCLN

BTG Pactual Global Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

BTG Pactual Global Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-43,829
Closed -$384K – 228
2014
Q4 		$384K Buy
+43,829
New +$355K 0.03% 128

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BTG Pactual Global Asset Management's SCLN Position: Q1 2015 in Review

BTG Pactual Global Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 43,829 shares — an estimated $384K sold.

BTG Pactual Global Asset Management first reported a position in SCLN in Q4 2014 and held it in 1 quarter. The position peaked at $384K in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • BTG Pactual Global Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 43,829 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $384K.
  • BTG Pactual Global Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • BTG Pactual Global Asset Management's Sciclone Pharmaceuticals Inc position peaked at $384K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on BTG Pactual Global Asset Management's 13F filing for Q1 2015, filed 14 May 2015.